By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of ...

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

The FDA has recalled thousands of Ziac blood pressure tablets after traces of a cholesterol drug were found during testing, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Some patients dropped out of the trial early because they had lost so much weight.

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

By Maggie Fick LONDON, Dec 11 (Reuters) - Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish ...